Emerging Joint Health Ingredients Target Faster Relief and Long-Term Support

The joint health supplement category continues to evolve as consumers seek products that not only support long-term joint health but also provide noticeable relief from discomfort in shorter time frames. As a result, ingredient suppliers are increasingly highlighting clinical validation, rapid onset of action, and formulation flexibility as differentiators to their success.

Small Dose and Fast Results

Joint health supplementation used to be a long-game: persistent supplementation to support joint structure and function. That is still important, but the sad reality is that people usually do not turn to joint health products until they begin to feel discomfort or even pain. Innovation in the joint health space has led to formulations that not only offer tangible relief in a short period of time but also a relatively small dose. For example, TamaFlex, a proprietary blend of Curcuma longa and Tamarindus indica extracts, from NXT USA has been evaluated in several human clinical studies investigating joint pain and function. According to Todd Runestad, chief storytelling officer at NXT USA, the ingredient—which works on the 5-LOX and COX-2 pathways—has shown relatively rapid effects in clinical research at a relatively low dose.

In one randomized clinical trial, 1,150 men and women between the ages of 40 and 70 years were assigned to receive a placebo, 250 mg of TamaFlex, or a 1000-mg blend of Curcuma longa and Boswellia serrata extracts for 30 days. Researchers evaluated outcomes using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).

Participants receiving TamaFlex experienced significant improvements in WOMAC scores compared with baseline and placebo. Improvements in knee pain and musculoskeletal function were reported as early as 5 days, a claim marketed on the formulation’s label. Researchers also observed reductions in biomarkers associated with inflammation and cartilage breakdown, including high-sensitivity C-reactive protein (hs-CRP) and urinary C-terminal cross-linked telopeptide of type II collagen (CTX-II).

In addition to patient-reported outcomes, Runestad noted that the studies have utilized various validation methods, noting that “Kenvue, which runs Tylenol, came out with their first supplement ever, just this past year. They chose TamaFlex because we have robust clinical trials, not just that it shows it works within five days, but what we call the 4 pillars of validation, which are patient assessment, physician validation, biomarker testing, blood tests, and then physical tests.”

Improving on a Classic

While some ingredients focus on addressing inflammatory pathways linked to joint discomfort, others target a joint’s structure itself. Chondroitin sulfate, a naturally occurring component of cartilage, has long been used in joint health supplements to support cartilage integrity and joint function. Often sourced from animals, other alternatives have come to market using fermentation as a means of production. For instance, MyCondro, developed by Gnosis by Lesaffre, is created via microbial fermentation and therefore free of animal derivatives.

“For a lot of consumers these days, the sustainability piece and being environmentally responsible is really important,” said Stacey Smith, senior medical affairs liaison for the Americas at Gnosis by Lesaffre. “Producing chondroitin through fermentation allows us to provide a high-quality, high-purity ingredient with consistent batches and low contamination risk.”

In addition to sustainability considerations, bioavailability is another factor influencing the development of joint health ingredients. This is crucial for the product’s effectiveness and for greater flexibility in dosing requirements. Lowering the effective dosage may give formulators more flexibility in developing multi-ingredient joint health products. According to Smith, bioavailability research conducted on MyCondro suggests improved absorption compared with some traditional sources of chondroitin sulfate.

“Because of the bioavailability study that we have, we’re showing that with a lower dose, it has better absorption,” Smith said. “You can actually use about half the dose compared with some animal-derived chondroitin sulfates. This is actually allowing people and formulators to make more innovative formulas, with the ability to combine more interesting ingredients.”

Smith noted that while many joint formulations emphasize anti-inflammatory activity, structural support remains an important aspect of joint health strategies.

“A lot of people are creating anti-inflammatory products,” Smith added. “What we really want to highlight is that chondroitin sulfate supports the actual joint and cartilage itself.”

These are welcome innovations that lead to creative and effective formulations in a category that has been somewhat static. Consumers want natural alternatives to over-the-counter pain meds, and industry is delivering.

Reference

1. Prasad N, Vinay V, Srivastava A. Efficacy of a proprietary combination of Tamarindus indica seeds and Curcuma longa rhizome extracts in osteoarthritis: a clinical investigation. Food Nutr Res. 2023;67. doi:10.29219/fnr.v67.9268